drugset / Trial / NCT03176498
Human Umbilical Cord Mesenchymal Stem Cell Therapy (19#iSCLife®-CI) for Cerebral Infarction Patients in Convalescent Period.
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a randomized, double-blind study. Human umbilical cord mesenchymal stem cells (hUC-MSC) will be treated on cerebral infarction patients, and evaluates their neurological function of convalescent period.
Timeline
- Start
- 2026-12-31
- Primary completion
- 2027-06-30
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SCLnow 19# | Cell therapy | — | Intravenous |
| Background | Aspirin | Small molecule | 0.1 g | Oral |
| Background | Atorvastatin | Small molecule | 20 mg | Oral |